PMID- 35023695
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220531
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 68
IP  - 1
DP  - 2022 Jan 1
TI  - Matrix Metalloproteinase 3: a Novel Effective Biomarker for Predicting the 
      Mortality and the Severity of Pneumonia.
LID - 10.7754/Clin.Lab.2021.210404 [doi]
AB  - BACKGROUND: Matrix metalloproteinase 3 (MMP3) is known as an inflammatory factor; 
      however, the effectiveness of MMP3 for diagnosis of pneumonia and predicting 
      outcomes is unclear. We evaluated the diagnostic and prognostic value of serum 
      MMP3 in patients with pneumonia. METHODS: One hundred and eighty-five patients 
      with pneumonia and 52 healthy controls were enrolled. Serum MMP3, neutrophil 
      gelatinase-associated lipocalin (NGAL), interleukin 6 (IL-6), procalcitonin 
      (PCT), and C-reactive protein (CRP) concentrations were measured at admission. 
      The patients were followed up for 90 days. RESULTS: Compared with healthy 
      controls, the concentrations of MMP3, NGAL, and IL-6 at admission were 
      significantly higher in patients with pneumonia (p < 0.05). The median 
      concentrations of MMP3, NGAL, and IL-6 were significantly higher in the patients 
      with severe pneumonia than the group of non-severe pneumonia (p < 0.05). Compared 
      with PCT (AUC = 0.778), CRP (AUC = 0.719), and IL-6 (AUC = 0.726), MMP3 (AUC = 
      0.846) and NGAL (AUC = 0.826) had significantly higher AUC values for 
      distinguishing the severity of pneumonia. The ROC of the combination of MMP3, 
      neutrophil to lymphocyte ratio (NLR), and D-dimer showed the best performance of 
      predicting pneumonia severity, which gave an AUC of 0.956. The AUC of MMP3 
      (0.950) for predicting mortality was highest, followed by NLR (AUC = 0.945), 
      D-dimer (AUC = 0.938), and NGAL (AUC = 0.913). Multivariable logistic regression 
      analysis showed MMP3, D-dimer, and NLR were the independent predictors of 
      hospital mortality in patients with pneumonia. Patients with MMP3 concentration > 
      124.3 ng/mL had a significantly higher risk of mortality (p < 0.05). CONCLUSIONS: 
      MMP3 is a valuable biomarker in assessment of the severity and prediction of 
      mortality in patients with pneumonia.
FAU - Wang, Fei
AU  - Wang F
FAU - Yang, Shuo
AU  - Yang S
FAU - Liu, Chong
AU  - Liu C
FAU - Xu, Zhen
AU  - Xu Z
FAU - Jia, Ke-Ke
AU  - Jia KK
FAU - Zhou, Jian-Suo
AU  - Zhou JS
FAU - Cui, Li-Yan
AU  - Cui LY
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Biomarkers)
RN  - 0 (IL6 protein, human)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipocalin-2)
RN  - 0 (Procalcitonin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Humans
MH  - Interleukin-6/blood
MH  - Lipocalin-2/blood
MH  - *Matrix Metalloproteinase 3/blood
MH  - *Pneumonia/diagnosis/mortality
MH  - Procalcitonin/blood
MH  - Prognosis
MH  - ROC Curve
EDAT- 2022/01/14 06:00
MHDA- 2022/01/18 06:00
CRDT- 2022/01/13 09:01
PHST- 2022/01/13 09:01 [entrez]
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
AID - 10.7754/Clin.Lab.2021.210404 [doi]
PST - ppublish
SO  - Clin Lab. 2022 Jan 1;68(1). doi: 10.7754/Clin.Lab.2021.210404.